Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 1

Published on: 

Dr. Nicole Faust, General Manager, Cell Line Development at Cytiva, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.


Dr. Nicole Faust has more than 20 years of management experience in the biotechnology sector. She joined Cytiva in 2022 through Cytiva’s acquisition of CEVEC. A member of the CEVEC team since 2011, she held several roles including CSO and CEO. She was instrumental in developing CEVEC´s unique ELEVECTA technology for scalable AAV production. Before joining CEVEC, she held leadership positions with Lonza and Taconic Biosciences. Her scientific background is in stem cell biology and she holds a PhD in cell and molecular biology from University of Freiburg and an MBA from Educatis University, Switzerland. Dr. Nicole Faust is well connected in the cell and gene therapy community, is a member of the American Society for Gene and Cell Therapy and currently Chair of the Gene Therapy Advisory Committee of the Alliance for Regenerative Medicine (ARM).

Register for the full webcast: https://www.pharmtech.com/pt_w/high-titre